Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × HCC × lenvatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 58 Cholangiocarcinoma 19 Carcinoma, Renal Cell 15 Biliary Tract Neoplasms 11 Thyroid Neoplasms 8 Stomach Neoplasms 8 Parkinson Disease 4, Autosomal Dominant Lewy Body 7 Endometrial Neoplasms 7 Neoplasms 6 Melanoma 6 Uterine Cervical Neoplasms 5 Thyroid Carcinoma, Anaplastic 5 Neuroendocrine Tumors 5 Carcinoma, Non-Small-Cell Lung 5 Recurrence 4 Liver Neoplasms 4 Thyroid Cancer, Papillary 3 Squamous Cell Carcinoma of Head and Neck 3 Small Cell Lung Carcinoma 3 Ovarian Neoplasms 3 Neoplasm Metastasis 3 Cirrhosis, Familial, with Pulmonary Hypertension 3 Brain Neoplasms 3 Advanced Biliary Tract Cancer 3 Adenocarcinoma, Follicular 3 Vulvar Neoplasms 2 Uveal Melanoma 2 Triple Negative Breast Neoplasms 2 Thymoma 2 Solid Tumors 2

Interventions

nimotuzumab 1 lenvatinib 1 atezolizumab 1 Sorafenib 1 Radiotherapy 1 Radiosurgery 1 Immune Checkpoint Inhibitors 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05873244 2025-03-21

CXD101 in Immunotherapy-related Liver Cancer

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡